Pediatric Wegovy Prescriptions Rise Sharply
The use of the GLP-1 drug for weight management in children has surged alongside rising national obesity rates.
Updated on Oct. 20, 2026 in Weight Loss
Live Poll
Do you trust the long-term safety of using GLP-1 drugs for children and teens?
Data shows pediatric Wegovy prescriptions jumped 310% in the United States between 2019 and 2026. This increase coincides with broader efforts to treat obesity, which currently affects approximately 20% of children in the U.S.
Why it matters
Wegovy remains the only weekly GLP-1 medication approved by the FDA for obesity in children over 12, serving as a significant intervention for adolescents. Clinical programs use this medication to address health concerns when traditional diet and exercise methods prove insufficient.
A case study at Hassenfeld Children's Hospital tracked a patient whose BMI dropped from 36 to 22.8 over two years. Researchers are currently studying the long-term effects of GLP-1 use in children, a group where 20% are classified as obese.
The players
Adam Renteria
He is a patient at the Adolescent Healthy Weight Program who successfully treated obesity using Wegovy and lifestyle changes.
Hassenfeld Children's Hospital
It is a medical institution that operates the Adolescent Healthy Weight Program and provides specialized endocrine care.
Food and Drug Administration
It is the federal agency responsible for evaluating the safety and efficacy of medical treatments, including GLP-1 medications.
The details
Adam Renteria received a prescription from a pediatric endocrinologist at the Adolescent Healthy Weight Program at Hassenfeld Children's Hospital. His treatment combined the medication with a dedicated regimen of physical activity and healthy food choices.
Timeline
Between 2019 and 2026, pediatric Wegovy prescriptions rose by 310%.
Adam Renteria underwent a two-year weight loss program ending in 2026.
Health Landscape
The surge in pediatric Wegovy usage follows the FDA approval for Wegovy in children over 12. This shift represents a move toward pharmacological interventions for obesity in a population where 20% of children are affected.
Families facing pediatric obesity concerns may find this option available through specialized pediatric endocrinology programs. Success often requires combining the medication with consistent lifestyle changes, including diet and exercise, under medical supervision.
The takeaway
Weight management in adolescents increasingly incorporates medical oversight and GLP-1 interventions. Successful long-term outcomes remain dependent on maintaining active physical habits and healthy nutritional choices alongside clinical treatment.
Further reading
Learn more about current approaches to childhood health at the United States Weight Loss section.
Source note: This article includes information reported by ABC News.
Live Poll
Do you trust the long-term safety of using GLP-1 drugs for children and teens?
